PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Rating) shares traded up 0.4% on Tuesday . The company traded as high as $2.88 and last traded at $2.84. 33,197 shares traded hands during mid-day trading, an increase of 276% from the average session volume of 8,831 shares. The stock had previously closed at $2.83.
PharmaCyte Biotech Stock Down 0.4 %
The company's fifty day moving average price is $2.93 and its two-hundred day moving average price is $2.87.
PharmaCyte Biotech Company Profile
(Get Rating)
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
Featured Stories
- Get a free copy of the StockNews.com research report on PharmaCyte Biotech (PMCBD)
- The Squeeze Is On For EVGo, Rally To Follow
- Is The Bottom In For RH, Or Is This Just A Stopping Point?
- Dividend King H.B. Fuller Signals Slowing In 2023
- Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
- 3 Companies That Just Started Paying Dividends
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.